Signals
59Adolescent depression care widens past SSRI defaults
Esketamine adolescent indication consideration, ECT and TMS adolescent access, structured measurement-based care, and integrated school-and-medical models are reshaping adolescent depression care.
Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Severe asthma management in pregnancy formalises around biologic continuation
Real-world evidence on biologic therapy continuation in pregnancy, structured high-risk pregnancy pulmonology integration, and updated guidelines are reshaping severe asthma in pregnancy.
Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Thyroid disease in pregnancy management formalises around structured monitoring
Pregnancy-specific TSH targets, structured pre-conception thyroid management, and integrated maternal-fetal medicine and endocrinology pathways are reshaping thyroid disease in pregnancy.
Treatment-resistant schizophrenia care formalises around clozapine integration
Clozapine pathway formalisation, KarXT muscarinic mechanism integration, and emerging mechanism-targeted programs are reshaping treatment-resistant schizophrenia.
Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Achondroplasia therapy options widen past vosoritide
Vosoritide commercial maturity and follow-on CNP analogue and FGFR3-targeted programs are restructuring achondroplasia management.
Dementia with Lewy bodies care formalises around alpha-synuclein-aware management
Cholinesterase inhibitor optimisation, antipsychotic-avoidance protocols, RBD recognition pathways, and emerging alpha-synuclein-targeted programs are reshaping DLB care.
CIDP therapy reshapes around FcRn antagonist class entry
Efgartigimod CIDP indication, follow-on FcRn antagonist programs, and structured maintenance protocols are reshaping chronic inflammatory demyelinating polyneuropathy management.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Congenital adrenal hyperplasia therapy reshapes around CRF1 receptor antagonism
Crinecerfont approval, follow-on CRF1 receptor antagonist programs, and structured care infrastructure are reshaping classic congenital adrenal hyperplasia management.
Autism spectrum disorder pharmacotherapy options widen past irritability indications
Risperidone and aripiprazole maturity for ASD-associated irritability, emerging mechanism-targeted programs for core symptoms, and integrated multidisciplinary care models are reshaping ASD pharmacotherapy.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
Genitourinary syndrome of menopause therapy widens past systemic hormone therapy
Vaginal estrogen formulation maturity, ospemifene and prasterone uptake, and emerging non-hormonal mechanism programs are restructuring genitourinary syndrome of menopause management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Pelvic floor disorder therapy options widen past Kegel-and-surgery defaults
Pelvic floor physiotherapy formalisation, vibegron and emerging beta-3 agonist programs in overactive bladder, and integrated multidisciplinary care models are reshaping pelvic floor disorders.
Chronic neuropathic pain therapy reshapes around novel sodium channel mechanisms
Suzetrigine (Nav1.8 inhibitor) acute pain approval and follow-on Nav1.8 and Nav1.7 programs in chronic pain are reshaping non-opioid pain management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Allergic conjunctivitis therapy widens past topical antihistamines
Topical multi-action options, novel mechanism programs, and emerging biologic-pathway therapy are reshaping allergic conjunctivitis management.
Cannabis use disorder pharmacotherapy programs reach late-stage trials
Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.
Alopecia areata therapy class competition matures
Baricitinib, ritlecitinib, and deuruxolitinib establish a competitive systemic JAK inhibitor class in severe alopecia areata.
Neuromyelitis optica spectrum disorder therapy class competition matures
Eculizumab, ravulizumab, satralizumab, inebilizumab, and emerging mechanism programs define a competitive NMOSD prescribing landscape.
Vasomotor symptom therapy expands past fezolinetant
Elinzanetant approval, follow-on NK3 receptor antagonist programs, and combination NK1-NK3 approaches are restructuring vasomotor symptom management.
Presbyopia pharmacological options widen past pilocarpine
Pilocarpine maturity, follow-on miotic-class programs, and emerging non-miotic mechanism programs are reshaping presbyopia management.
Spinal muscular atrophy long-term outcome data reshapes treatment expectations
Multi-year outcome data across nusinersen, onasemnogene abeparvovec, and risdiplam plus emerging combination strategies are clarifying long-term SMA treatment expectations.
Restless legs syndrome therapy reshapes around augmentation avoidance
Alpha-2-delta ligand first-line preference, low-dose opioid use, and novel mechanism programs are restructuring restless legs syndrome management.
Post-stroke spasticity therapy options widen past oral baclofen
Botulinum toxin maturity, intrathecal baclofen pump access, and emerging novel mechanism programs are reshaping post-stroke spasticity management.
Breast cancer survivorship care widens past tamoxifen and aromatase inhibitor side-effect management
Vasomotor symptom therapy in breast cancer survivors, bone-health management with aromatase inhibitors, and structured survivorship programs are reshaping breast cancer survivorship care.
Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Insomnia comorbid with mental health conditions acquires structured therapy options
Daridorexant maturity, cognitive-behavioural therapy for insomnia (CBT-I) digital expansion, and integrated mental-health-and-insomnia treatment models are reshaping comorbid insomnia care.
Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Lupus nephritis therapy options mature past induction-and-maintenance
Voclosporin and belimumab in lupus nephritis plus emerging mechanism programs are restructuring induction and maintenance therapy.
Hemophilia gene therapy real-world data starts to clarify durability
Approved factor VIII and factor IX gene therapy products are accumulating real-world durability data that defines the addressable-population reality.
Postmenopausal osteoporosis therapy reshapes around anabolic-first sequencing
Romosozumab maturity, ongoing teriparatide and abaloparatide use, and follow-on anabolic programs are restructuring postmenopausal osteoporosis sequencing.
Pre-eclampsia prediction and prevention infrastructure matures
sFlt-1 to PlGF ratio testing in suspected pre-eclampsia and aspirin-prophylaxis pathway adoption are reshaping pre-eclampsia care.
Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
Dementia behavioural symptoms acquire approved pharmacotherapy
Brexpiprazole approval for agitation in Alzheimer's dementia and follow-on programs are reshaping dementia behavioural symptom management.
Thyroid eye disease therapy grows past teprotumumab
Teprotumumab maturity plus follow-on IGF-1R-targeted programs and novel non-IGF-1R mechanism classes are restructuring thyroid eye disease management.
Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Hereditary angioedema oral options reach maturity
Oral plasma kallikrein inhibitors and emerging factor XIIa inhibitor programs are restructuring HAE prophylaxis and on-demand therapy.
Diabetic peripheral neuropathy therapy advances after a long quiet period
Capsaicin patch maturity, novel sodium channel modulators, and emerging disease-modifying programs are reshaping diabetic peripheral neuropathy management.
Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Obsessive-compulsive disorder modern options mature
Deep brain stimulation maturity, novel glutamate-modulator programs, and refined transcranial magnetic stimulation protocols are reshaping refractory OCD management.
Tardive dyskinesia therapy access patterns
Approved VMAT2 inhibitor therapy for tardive dyskinesia continues to expand but underdiagnosis remains the primary gap.
Vaping-associated lung disease as a recognised category
EVALI (e-cigarette and vaping-associated lung injury) and chronic bronchiolitis from vaping are now recognised pulmonology diagnostic categories.
PAH combination therapy moves to first-line
Pulmonary arterial hypertension upfront combination therapy is becoming standard rather than sequential single-agent escalation.
Uterine fibroid GnRH antagonist combination therapy is displacing surgical-only management
GnRH antagonist combination therapy (with add-back hormone) for uterine fibroids has expanded medical management options for a condition that was historically managed primarily through surgery. The commercial implications across surgical referral patterns, fertility-preservation framing, and adjacent gynaecological pipeline are material.
Long-acting injectable antipsychotic uptake reveals adherence-versus-access gap in schizophrenia
Real-world uptake of long-acting injectable (LAI) antipsychotics in schizophrenia is well below the eligible-population estimate across major markets, despite strong adherence and outcome benefits. The drivers are access infrastructure, prescriber inertia, and patient-pathway operational complexity.
TYK2 inhibitor commercial uptake in psoriasis is reshaping the oral-versus-injection conversation
TYK2 inhibitor uptake in psoriasis is establishing the first commercially meaningful oral biologic alternative for moderate-to-severe disease. The route-of-administration conversation is now active in a way it has not been in the IL-23 and IL-17 era.
Postpartum depression novel mechanism uptake reveals the maternal-mental-health access gap
The approval of zuranolone for postpartum depression introduced a rapid-acting oral mechanism into a previously underserved indication. Real-world uptake patterns reveal the structural access gap in maternal mental health, with material implications for the commercial trajectory of adjacent maternal mental health pipeline.
Friedreich's ataxia real-world treatment uptake reveals the access-versus-efficacy gap
Real-world uptake of the first approved disease-modifying therapy for Friedreich's ataxia has been slower and more uneven than the pivotal trial population would have predicted. The drivers are infrastructure, payer behaviour, and patient-specialist matching, not the underlying clinical evidence.
Caregiver support is becoming part of the Alzheimer's policy frame
CMS's GUIDE Model and adjacent caregiver-support policy are reshaping how dementia care is paid for outside the medication and diagnostic frame.
Snapshots
35Cardiac amyloidosis therapy reference (2026)
Reference snapshot of cardiac amyloidosis therapy across AL and ATTR types.
Achondroplasia therapy reference (2026)
Reference snapshot of achondroplasia care across supportive, surgical, and disease-modifying tiers.
Treatment-resistant schizophrenia therapy reference (2026)
Reference snapshot of TRS therapy across clozapine, augmentation, and emerging mechanism tiers.
Retinal vein occlusion therapy reference (2026)
Reference snapshot of RVO therapy across acute and ongoing macular edema management plus systemic care integration.
Thyroid cancer therapy reference (2026)
Reference snapshot of thyroid cancer therapy across differentiated, medullary, and anaplastic subtypes.
Dementia subtype therapy reference (2026)
Reference snapshot of dementia therapy across Alzheimer's, dementia with Lewy bodies, vascular, and frontotemporal subtypes.
Allergic bronchopulmonary aspergillosis therapy reference (2026)
Reference snapshot of ABPA therapy across acute, recurrent, and emerging biologic-integrated tiers.
Systemic sclerosis therapy reference (2026)
Reference snapshot of systemic sclerosis therapy across organ-domain-specific and emerging disease-modifying tiers.
Nausea and vomiting in pregnancy therapy reference (2026)
Reference snapshot of nausea and vomiting in pregnancy therapy from mild morning sickness through hyperemesis gravidarum.
Cholangiocarcinoma therapy reference (2026)
Reference snapshot of cholangiocarcinoma therapy across resectable and advanced disease and biomarker-defined targeted tiers.
ANCA-associated vasculitis therapy reference (2026)
Reference snapshot of ANCA-associated vasculitis therapy across induction, maintenance, and refractory disease.
Chronic inflammatory demyelinating polyneuropathy therapy reference (2026)
Reference snapshot of CIDP therapy across induction, maintenance, and emerging biologic tiers.
Overactive bladder therapy reference (2026)
Reference snapshot of overactive bladder therapy across behavioural, pharmacological, and procedural tiers.
Allergic conjunctivitis therapy reference (2026)
Reference snapshot of allergic conjunctivitis therapy across mild seasonal, persistent, severe, and emerging tiers.
Phenylketonuria therapy reference (2026)
Reference snapshot of PKU therapy across newborn-screened, paediatric, and adult populations.
Autism spectrum disorder care reference (2026)
Reference snapshot of ASD care across behavioural therapy, educational support, pharmacotherapy for associated symptoms, and emerging core-symptom programs.
Severe COPD therapy reference (2026)
Reference snapshot of severe COPD therapy across foundational inhaler, biologic, and emerging mechanism tiers.
Spasticity therapy reference (2026)
Reference snapshot of spasticity therapy across post-stroke, multiple sclerosis, cerebral palsy, and spinal cord injury populations.
Tobacco use disorder therapy reference (2026)
Reference snapshot of tobacco use disorder therapy across pharmacotherapy, behavioural support, and integrated care models.
Spinal muscular atrophy therapy reference (2026)
Reference snapshot of SMA therapy options across newborn-screened, symptomatic infant, child, and adult populations.
Lupus nephritis therapy reference (2026)
Reference snapshot of lupus nephritis therapy across induction and maintenance phases.
Presbyopia therapy reference (2026)
Reference snapshot of presbyopia management across optical, surgical, and pharmacological approaches.
Obstructive sleep apnea therapy reference (2026)
Reference snapshot of OSA therapy across positive airway pressure, oral appliances, surgery, neurostimulation, and emerging pharmacotherapy.
HFrEF therapy reference (2026)
Reference snapshot of HFrEF therapy across the four-pillar standard, additional approved options, and emerging mechanism classes.
Adult diffuse glioma therapy reference (2026)
Reference snapshot of adult diffuse glioma therapy across IDH-mutant grade 2/3 disease, glioblastoma first-line, and recurrent disease.
Vasomotor symptom therapy reference (2026)
Reference snapshot of vasomotor symptom therapy across hormone, non-hormonal pharmacotherapy, and emerging mechanism-targeted tiers.
Sjogren disease therapy reference (2026)
Reference snapshot of Sjogren disease therapy across symptomatic, off-label, and emerging mechanism-targeted tiers.
Refractory chronic cough therapy reference (2026)
Reference snapshot of refractory chronic cough therapy across symptomatic, off-label, and emerging targeted tiers.
Thyroid eye disease therapy reference (2026)
Reference snapshot of thyroid eye disease therapy across active and stable phases.
OCD therapy reference (2026)
Reference snapshot of OCD therapy across pharmacotherapy, psychotherapy, and procedural-and-emerging tiers.
Hepatocellular carcinoma therapy reference (2026)
Reference snapshot of HCC therapy across early, intermediate, and advanced disease.
Acute ischemic stroke therapy reference (2026)
Reference snapshot of acute ischemic stroke therapy across thrombolysis and mechanical thrombectomy.
Postmenopausal osteoporosis therapy reference (2026)
Reference snapshot of postmenopausal osteoporosis therapy across anti-resorptive and anabolic tiers.
Migraine prevention therapy class reference (2026)
Reference snapshot of approved migraine prevention options including CGRP class, traditional preventives, and emerging mechanisms.
Caregiver support landscape for Alzheimer's disease, as of Q2 2026
A reference view of the federal, state, employer, and direct-support programs that currently exist for unpaid family caregivers of people with Alzheimer's disease in the US, with notes on the UK and EU.
Explained
45What is AL amyloidosis?
Plain-language primer on AL amyloidosis, why early diagnosis matters so much, and how modern therapy works.
What is hyperemesis gravidarum?
Plain-language primer on hyperemesis gravidarum, why it is more than morning sickness, and what comprehensive care can offer.
What is treatment-resistant schizophrenia?
Plain-language primer on treatment-resistant schizophrenia, why clozapine matters, and what comprehensive care looks like.
What is systemic sclerosis?
Plain-language primer on systemic sclerosis (scleroderma), why it affects multiple organ systems, and what modern therapy can offer.
What is allergic bronchopulmonary aspergillosis?
Plain-language primer on ABPA, why it is different from typical asthma, and how modern therapy works.
What is achondroplasia?
Plain-language primer on achondroplasia, why it is the most common skeletal dysplasia, and what the new therapy options can offer.
What is thyroid cancer?
Plain-language primer on thyroid cancer, why molecular profile now matters, and how modern therapy works.
What is dementia with Lewy bodies?
Plain-language primer on dementia with Lewy bodies, why it is different from Alzheimer's, and how modern care works.
What is retinal vein occlusion?
Plain-language primer on retinal vein occlusion, why it is a vascular event, and what modern therapy can offer.
Autism spectrum disorder care explained
Plain-language primer on ASD care, why it is multidisciplinary, and what is changing in pharmacotherapy.
PCSK9 inhibitors and modern lipid therapy explained
Plain-language primer on PCSK9 and the modern range of lipid-lowering options.
What is ANCA-associated vasculitis?
Plain-language primer on ANCA-associated vasculitis, why it can affect multiple organs, and how modern therapy works.
What is cholangiocarcinoma?
Plain-language primer on cholangiocarcinoma, why molecular profiling now matters so much, and how modern therapy works.
What is overactive bladder?
Plain-language primer on overactive bladder, why it is common, and what the modern therapy options can offer.
What is chronic inflammatory demyelinating polyneuropathy?
Plain-language primer on CIDP, why immune therapy is the foundation, and what the modern options can offer.
What is phenylketonuria?
Plain-language primer on phenylketonuria, why early diagnosis matters so much, and what the modern therapy options can offer.
What is allergic conjunctivitis?
Plain-language primer on allergic conjunctivitis, the different types, and what the modern range of therapy can offer.
Severe COPD and biologic therapy explained
Plain-language primer on severe COPD, why biologic therapy is now an option for some patients, and what the modern combined approach can offer.
What is tobacco use disorder?
Plain-language primer on tobacco use disorder, why quitting is difficult, and what the modern combined approach can offer.
What is lupus nephritis?
Plain-language primer on lupus nephritis, why kidney involvement is a turning point in lupus, and how modern therapy works.
What are vasomotor symptoms?
Plain-language primer on hot flashes and night sweats, why they happen, and what the modern therapy options can offer.
What is spinal muscular atrophy?
Plain-language primer on SMA, why genetics drives the disease, and how the modern therapy options work.
What is presbyopia?
Plain-language primer on presbyopia, why it affects nearly everyone with age, and what the modern range of options can offer.
What is glioblastoma?
Plain-language primer on glioblastoma, why it has been so hard to treat, and what is changing in glioma therapy.
What is obstructive sleep apnea?
Plain-language primer on obstructive sleep apnea, why CPAP has been the standard, and what is changing in OSA therapy.
What is spasticity?
Plain-language primer on spasticity, why it happens after neurological injury, and what the therapy options can offer.
What is heart failure?
Plain-language primer on heart failure, why the modern therapy is built around four foundational classes, and what is changing.
Acute ischemic stroke explained
Plain-language primer on acute ischemic stroke, why time matters, and how modern therapy works.
What is hepatocellular carcinoma?
Plain-language primer on hepatocellular carcinoma, why it usually develops on a background of liver disease, and how the modern therapy options compare.
What is type 1 diabetes?
Plain-language primer on type 1 diabetes, what is changing, and how modern therapy works.
What is obsessive-compulsive disorder?
Plain-language primer on OCD, why it has multiple subtypes, and what therapy can offer.
What is thyroid eye disease?
Plain-language primer on thyroid eye disease, why it is linked to thyroid problems, and what modern therapy can offer.
What is Sjogren disease?
Plain-language primer on Sjogren disease, why it has been hard to treat, and what is changing.
What is hereditary angioedema?
Plain-language primer on hereditary angioedema, why it is different from allergy, and how modern therapy works.
Postmenopausal osteoporosis explained
Plain-language primer on postmenopausal osteoporosis, why bone changes after menopause, and how modern therapy works.
What is refractory chronic cough?
Plain-language primer on refractory chronic cough, why it is a distinct condition, and what is changing in therapy.
How contraception innovation is being reshaped by the long-acting reversible class
Contraceptive innovation has shifted from oral and short-acting options toward long-acting reversible contraception (LARC) including hormonal IUDs, copper IUDs, and contraceptive implants. The commercial logic, the access frame, and the implications for the broader reproductive health pipeline are worth understanding.
What are CSF biomarkers, and how do they fit alongside plasma and PET?
CSF biomarkers - measured in cerebrospinal fluid obtained by lumbar puncture - are well-validated tests for Alzheimer's pathology that pre-date both plasma biomarkers and broad amyloid PET access. They remain in routine clinical use, particularly where PET is not available and where the diagnostic question is complex enough to warrant the procedural friction.
What is tau PET, and how is it different from amyloid PET?
Tau PET is a brain scan that shows the build-up of tau, the second protein associated with Alzheimer's disease. The image is closer to the clinical picture than amyloid is - tau accumulation tracks more directly with where and how a person is currently impaired. The trade-off is that tau PET is harder to access than amyloid PET, and the access gap is now a rate-limiter on multiple fronts.
What is mild cognitive impairment, and how is it different from "early Alzheimer's"?
Mild cognitive impairment (MCI) is a diagnostic category, not a disease. It describes cognitive decline that is more than expected for age but not severe enough to count as dementia. When that decline is caused by underlying Alzheimer's pathology, the term you will increasingly hear in clinical-trial and treatment settings is "early Alzheimer's disease" - which means MCI due to Alzheimer's plus mild dementia due to Alzheimer's, taken together.
What is co-pathology in dementia, and why does it matter?
Co-pathology means more than one disease process is contributing to someone's symptoms at the same time. In older patients with cognitive symptoms, mixed pathology is the rule, not the exception.
What is the CMS GUIDE Model, and who is it for?
The Guiding an Improved Dementia Experience (GUIDE) Model is a Medicare payment pathway for comprehensive dementia care - including direct support for family caregivers. It pays participating practices to deliver a coordinated care package that standard Medicare doesn't.
What is ALZ-NET, and what does it do with patient data?
ALZ-NET is the Alzheimer's Network for Treatment and Diagnostics - the main patient registry collecting real-world data on people receiving anti-amyloid therapy in the US. It is the registry that Medicare's coverage-with-evidence-development framework routes patients through.
What is amyloid PET, and when is it used?
Amyloid PET is a brain scan that shows whether the amyloid protein associated with Alzheimer's disease has built up in the brain. It is used to confirm or rule out Alzheimer's pathology when the diagnosis matters.
What are plasma biomarkers in Alzheimer's disease?
Plasma biomarkers are blood tests that look for proteins associated with Alzheimer's disease pathology. The most clinically useful one in 2026 is plasma p-tau217.